Risankizumab-rzaa
Risankizumab-rzaa Uses, Dosage, Side Effects, Food Interaction and all others data.
Risankizumab-rzaa is a fully humanized IgG1 monoclonal antibody (mAb) that is selective for interleukin 23 (IL-23). On April 23, 2019 it was approved by the FDA (as SKYRIZI) for the treatment of moderate-to-severe plaque psoriasis in adults who are clinically considered eligible for systemic therapy or phototherapy for psoriasis. This drug has been commercialized through collaboration between the German pharmaceutical company, Boehringer Ingelheim, and Abbvie.
Psoriasis is a chronic inflammatory disease of the skin most commonly characterized by raised, red plaques covered with silver scales in cases of plaque psoriasis. There are several subtypes of psoriasis, however, plaque psoriasis is most prevalent. This disease occurs mainly in adults (with a prevalence ranging from 0.91% to 8.5%). Psoriasis has a peak incidence at two age groups: approximately 30–39 years and approximately 60 years of age. Depending on disease severity, psoriasis may have significant effects on quality of life and can lead to embarrassment and negative social consequences. Risankizumab-rzaa is a promising drug for the relief of plaque psoriasis and has been shown to be effective in managing the above unpleasant symptoms.
No formal studies examining pharmacodynamic properties have been completed with risankizumab , however, this drug is expected to relieve symptoms of psoriasis by targeting interleukin 23 (IL-23) and preventing the initiation of the inflammatory cascade that is implicated in psoriasis.
| Trade Name | Risankizumab-rzaa |
| Availability | Prescription only |
| Generic | Risankizumab |
| Risankizumab Other Names | Risankizumab, risankizumab-rzaa |
| Related Drugs | Skyrizi, Tremfya, Entyvio, Humira, Otezla, Stelara, Cosentyx, prednisone, methotrexate, budesonide |
| Type | Subcutaneous |
| Formula | C6476H9992N1720O2016S44 |
| Weight | 145600.0 Da |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Risankizumab-rzaa is an interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.
This drug is for the treatment of moderate-to-severe plaque psoriasis in adults who are eligible to receive systemic therapy or phototherapy based on their disease process.
Risankizumab-rzaa is also used to associated treatment for these conditions: Moderate plaque-type psoriasis, Psoriasis, Severe plaque-type psoriasis, Moderate, severe Psoriasis Vulgaris (Plaque Psoriasis)
How Risankizumab-rzaa works
Risankizumab-rzaa acts to prevent the release of pro-inflammatory cytokines and chemokines that often lead to inflammatory skin symptoms, such as redness, pain, and plaques. Risankizumab-rzaa binds with a high affinity to the p19 subunit of human interleukin 23 (IL-23) cytokine , thereby preventing its action on the IL-23 receptor. IL-23 is a cytokine released in the human body that is involved in inflammatory and immune processes, especially in peripheral tissues.
IL-23 plays a role in polarized type-1 T cell-mediated inflammatory response. Type-1 T cells are found in very high concentrations in psoriasis-affected skin in addition to the blood of psoriasis patients. By promoting the action of interferon (IFN)-gamma , type-1 T cells increase the expression of many inflammatory genes that induce inflammatory cascades . Variants of the gene encoding IL-23 p19 subunit and the IL-23 receptor have been recognized as part of the pathogenesis of plaque psoriasis, rendering IL-23 an ideal target for risankizumab therapy.
Toxicity
Overdosage
In cases of overdose, ensure to monitor the patient for any signs or symptoms of adverse reactions and provide supportive treatment accordingly.
Carcinogenesis and mutagenesis
Currently, no studies examining carcinogenic potential or mutagenic potential have been conducted using this drug.
Use in pregnancy
There are limited data regarding the administration of risankizumab in pregnant women. An associated risk of major birth defects, miscarriage, or adverse effects on the mother or fetus is not yet established . It is important to note, however, that human IgG is known to cross the placenta, and this drug may similarly be transmitted to the growing fetus. Risankizumab-rzaa belongs to an IgG antibody subclass and likely shares similar properties . The Canadian monograph for risankizumab indicates that women of childbearing potential should take adequate contraception during therapy and for at least 20 weeks after the final dose.
Use during nursing
Currently, there are no available data regarding risankizumab in human milk, its effect on the production of milk, and its effect on a nursing child. Maternal IgG is, however, found to be excreted in human milk. This drug belongs to an IgG subclass, and may share similar properties. The benefits of breastfeeding should be considered in addition to the mother's requirement for risankizumab and any possible risks resulting from nursing while taking this drug, which is likely to be present in human milk.
Food Interaction
No interactions found.Risankizumab-rzaa Drug Interaction
Unknown: charcoal, nifedipine, irbesartan, sucralfate, sulfamethoxazole / trimethoprim, ubiquinone, copper gluconate, ethanol, glycerin, heparin, sodium iodide, arginine, levocarnitine, cysteine, insulin glargine, fenofibrate, lithium, vitamin a topical, bioflavonoids, sotalol
Risankizumab-rzaa Disease Interaction
Moderate: hepatic/renal, infections, TB infection, vaccinations
Volume of Distribution
The approximate volume of distribution at steady state is 11.2 L (34%) in patients diagnosed with plaque psoriasis, but may vary with increased body weight.
Elimination Route
The absolute bioavailability of risankizumab is estimated at approximately 89% after a dose given by subcutaneous injection. In a clinical study, peak concentration (Cmax) was reached within 3-14 days after beginning risankizumab therapy.
In patients diagnosed with psoriasis, estimated risankizumab trough plasma concentrations were found to be 1.72 ± 1.11 at week 16 of treatment and 1.36 ± 0.923 µg/mL at week 52 of treatment, using a predictive pharmacokinetic model.
The area under the curve (AUC) curve at steady state (study weeks 40–52) was predicted at 344 ± 151 µg/day/mL .
Half Life
The half-life of risankizumab is about 28 days in patients with plaque psoriasis.
Clearance
Systemic clearance is estimated at 0.31 L per day (24%). One study found that interindividual clearance for risankizumab varied by 37%. Risankizumab-rzaa clearance is found to decrease with an increase in body weight. Despite this tendency, no dose adjustment is advised in overweight patients.
Innovators Monograph
You find simplified version here Risankizumab-rzaa
